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Summary and Implications 
 The immune response of newborn calves to early 
vaccination is often variable and frequently characterized by 
marginal or nonexistent antibody responses.  The B cell 
subpopulation of immune cells is pivotal in the production 
of antibody and has not been characterized completely in the 
newborn calf.  Results from this research describe the 
composition and antigen-specific responses of B cell 
populations in preruminant calves vaccinated at an early 
age. Although preliminary, these data indicate that the 
responsiveness of B cell population in young calves is 
dependent on the nature of the vaccine and less on animal 
maturity. This research provides important new information 
regarding the immune responsiveness of the neonatal calf to 
vaccination.  
 
       Introduction 
 Economic losses associated with infectious diseases in 
preruminant calves are substantial. The mortality rate for 
pre-weaned dairy calves is approximately 8 to 11% and the 
morbidity rate is approximately 37%. 
 The calf is born without measurable serum 
immunoglobulin and relies on ingestion of colostrum for 
establishment of passive immunity. Ingestion of colostrum 
is necessary for acquisition of protective maternal Ig; 
however, it has been suggested that colostral Ig 
compromises adaptive immune responses of vaccinated 
calves. For example, neonatal calves fail to develop antigen-
specific Ig (i.e. antibody, Ab) responses to Brucella abortus 
if antigen-specific maternal Ab is present at the time of 
vaccination. In the absence of colostral Ab, calves develop 
vigorous Ab responses to B. abortus. Preruminant calves 
sensitized to ovalbumin (OVA) (an antigen to which there 
was no maternal Ig) at birth mount humoral responses 
similar to older cattle, regardless of colostral status.  
Likewise, neonatal calves vaccinated with an attenuated 
strain of Mycobacterium bovis (strain BCG) fail to mount 
measurable Ab responses; however, they do develop 
vigorous cell-mediated immune responses. In addition, 
calves given a Bovine Viral Diarrhea virus vaccine develop 
antigen-specific CD4+, CD8+, and γδ TCR+ cell responses 
and generate memory T and B cells, despite primary 
humoral responses being blocked by maternal Ab. These 
results suggest that although maternal Ab may block the 
vaccinated calf’s antibody response, its B cell population 
retains the capacity to differentiate into memory B cells.   
 The present study characterized the composition and 
function of B cell populations from neonatal calves 
vaccinated at an early age with OVA and BCG. Ovalbumin 
was selected because it is not encountered in the natural 
environment of cattle and it has been shown that the 
magnitude of Ab responses of neonatal and adult cattle to 
this antigen is similar. BCG was utilized because it induces 
an Ab response in adult cattle but not in colostrum-fed 
neonatal calves, presumably due to blocking maternal Ab 
resulting from exposure of dams to environmental 
mycobacteria.  Potential effects of BCG vaccination on 
OVA-specific Ab responses were also considered. 
 
Materials and Methods 
 Vaccination Schedule for Experiment 1: Six Holstein 
bull calves were acquired at <4 d of age. Calves in this 
experiment and Experiment 2 (see below) each received 3.9 
L of fresh colostrum within 6h of birth.  At 3 wk of age, all 
calves were vaccinated subQ in the mid-cervical region, left 
side of the neck, with OVA/incomplete Freund’s adjuvant 
(IFA).  On the same day, 3 calves were vaccinated subQ in 
the right mid-cervical region of the neck with BCG. All 
calves were revaccinated with OVA/IFA at 5 wk of age. 
 Vaccination Schedule for Experiment 2: Holstein bull 
calves (24) were acquired at <5 d of age. At 3 wk of age, all 
were vaccinated subQ in the left mid-cervical region of the 
neck with OVA.  On the same day, all calves were 
vaccinated with BCG (subQ in the right mid-cervical 
region). All calves were revaccinated with OVA at 5 wk of 
age (14d after initial sensitization). Six calves (n = 6) were 
euthanized at 7 wk of age. Superficial cervical lymph nodes 
from both sides of the neck were harvested. 
 Antigens: Recall antigens were OVA and M. bovis 
purified protein derivative (PPD).  A proteinase K-digested 
whole cell sonicate of M. bovis BCG (WCS-PK) was used 
as capture antigen.  
 Measurement of Ig in Serum and in Culture 
Supernatants: Antigen-specific IgG1 and IgG2 
concentrations were determined for serum samples collected 
weekly before and after vaccination. OVA-specific and 
WCS-PK-specific Ig concentrations in supernatant from 
non-stimulated and antigen-stimulated immune cell cultures 
were evaluated using a capture ELISA. 
 Activation Molecule Expression on B cells Isolated 
from Lymph Nodes: Mononuclear cells recovered from 
superficial cervical lymph nodes were used to establish 
cultures in microtiter plates.  Cultures were not stimulated 
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(media only), stimulated with OVA, and stimulated with 
PPD and subsequently incubated for 3 or 6 d at 39°C in a 
5% CO2 atmosphere. Cells were phenotyped by flow 
cytometry (Table 1). Cells exhibiting light scattering 
properties consistent were bovine mononuclear cells were 
analyzed. 
 
 
 
 
Table 1.  Primary and secondary antibodies used in flow 
analysis of cervical lymph node cells from vaccinated calves.  
 
 
Results and Discussion 
 Vaccination of 3-wk old calves with OVA elicited 
measurable Ab responses (Figure 1) that were amplified by 
revaccination supporting previous research demonstrating 
that the neonatal calf possesses the capacity to produce Ab 
responses to antigens not present in the natural environment. 
OVA-specific recall responses of B cells from lymph nodes 
draining the OVA vaccination site (Table 2) were 
characterized by decreased CD5, CD21, and CD40 
expression and increased BB2, CD25, and CD80 
expression. Vaccination with BCG, in contrast, did not 
augment existing levels of mycobacteria-specific Ab (Figure 
2). PPD-induced recall responses of B cells from lymph 
nodes draining the site of BCG vaccination site (Table 3) 
were characterized by increased CD25 and CD80 expression 
suggesting that although maternal Ab may block 
endogenous Ab production, the calf’s B cells are still 
activated by BCG vaccination. Interestingly, B cells from 
lymph nodes draining the vaccination site, but not from the 
opposing side of the body, responded to antigenic 
stimulation, suggesting initiation and maturation of adaptive 
immune responses are localized within nodes draining the 
vaccination site. Overall, these data indicate that the 
responsiveness of B cells in neonatal calves is dependent on 
the nature of the vaccine and less on animal maturity.  
Future studies will consider the effects of the colostral Ab 
on responses of calves to early vaccination and infection. 
 
Table 2.  Expression of activation molecules on IgM+ B cells 
and CD5+IgM+ B cells isolated from left superficial cervical 
lymph nodes draining the OVA vaccination site. 
Stimulation  
Cell Phenotype Nonstimulated OVA PPD 
IgM+ B cells    
  % CD5  66.2 ±  2.6a 49.4 ± 4.3b 61.7 ± 2.2a 
  CD5 MFI 67.8 ± 10.9a 25.3 ± 6.2b 45.3 ± 6.4ab 
  % B-B2  37.6 ±  2.9a 54.0 ± 3.2b 42.0 ± 2.0a 
  B-B2 MFI   7.5 ±  0.7a 12.0 ± 1.3b   8.5 ± 0.6a 
  CD21 MFI   4.9 ±  0.2a   4.2 ± 0.2b   4.7 ± 0.2ab 
  CD25 MFI   4.0 ±  0.3a   7.0 ± 0.8b   4.9 ± 0.3a 
  MHC-II MFI   5.6 ±  0.7   9.2 ± 1.7   7.0 ± 1.0 
  CD11a/18 MFI 11.1 ±  0.9   8.6 ± 0.9 10.5 ± 1.0 
  CD80 MFI   4.5 ±  0.5a   6.8 ± 0.5b   5.3 ± 0.4a 
  CD40 MFI   5.8 ±  0.4a   4.5 ± 0.3b   5.1 ± 0.3ab 
CD5+IgM+B cells    
  % B-B2 17.2 ± 1.96a 30.5 ± 2.5b 22.7 ± 1.0a 
  B-B2 MFI   3.7 ± 0.2a   4.8 ± 0.2b   4.0 ± 0.2a 
  CD21 MFI   4.9 ± 0.3a   4.0 ± 0.2b   4.5 ± 0.3ab 
  CD25 MFI   3.0 ± 0.2a   5.0 ± 0.6b   3.7 ± 0.2a 
  MHC-II MFI   2.8 ± 0.1a   4.1 ± 0.5b   3.4 ± 0.2ab 
  CD11a/18 MFI 14.1 ± 0.9 12.4 ± 1.2 14.4 ± 1.2 
  CD80 MFI   3.3 ± 0.3a   4.1 ± 0.2b   3.8 ± 0.2ab 
  CD40 MFI   5.2 ± 0.3a   4.2 ± 0.3b   4.8 ± 0.4ab 
1 Left superficial cervical lymph node cells from calves vaccinated with 
OVA on the left side of the neck at 3- and 5-wk of age and with BCG on 
the right side of the neck at 3 wk of age.  At 7-wk of age lymph nodes were 
harvested and cultured in vitro in absence and presence of antigens (OVA 
and PPD). Mean fluorescence intensities (MFI; + SEM) and percent of 
IgM+B cells and CD5+IgM+ B cells positive for each phenotype are shown.  
ab Means within a row with different superscripts differ (P < 0.05). 
 
Table 3.  Expression of activation molecules on IgM+ B cells 
and CD5+IgM+ B cells from right superficial cervical lymph 
nodes draining the BCG vaccination site. 
Stimulation1  
Cell Phenotype NS OVA PPD 
IgM+ B cells    
  % CD5  66.3 ±  3.7 66.2 ± 2.8 60.0 ± 3.6 
  CD5 MFI 64.7 ± 15.1 54.7 ± 8.5 39.4 ± 7.4 
  % B-B2  40.2 ±  4.4 43.3 ± 2.8 45.3 ± 2.0 
  B-B2 MFI   7.8 ±  0.7   8.3 ± 0.6   9.6 ± 0.9 
  CD21 MFI   5.0 ±  0.1   4.9 ± 0.2   4.8 ± 0.2 
  CD25 MFI   4.2 ±  0.4a   4.6 ± 0.3a   6.1 ± 0.5b 
  MHC-II MFI   6.1 ±  1.0   6.3 ± 0.8   8.9 ± 1.8 
  CD11a/18 MFI 10.8 ±  1.1   9.9 ± 0.5 11.0 ± 1.4 
  CD80 MFI   4.9 ±  0.4a   5.4 ± 0.4ab   6.3 ± 0.5b 
  CD40 MFI   5.4 ±  0.1   5.0 ± 0.2   5.1 ± 0.2 
CD5+IgM+B cells    
  % B-B2  20.5 ± 3.3 24.7 ± 2.5 27.0 ± 2.1 
  B-B2 MFI   4.0 ± 0.3   4.5 ± 0.2   4.4 ± 0.2 
  CD21 MFI   4.9 ± 0.2   4.8 ± 0.3   4.6 ± 0.3 
  CD25 MFI   3.1 ± 0.2a   3.5 ± 0.2a   4.9 ± 0.4b 
  MHC-II MFI   2.9 ± 0.1a   3.3 ± 0.2a   4.2 ± 0.4b 
  CD11a/18 MFI 13.3 ± 1.0ab 12.1 ± 0.6a 15.0 ± 0.8b 
  CD80 MFI   3.7 ± 0.2a   4.1 ± 0.2ab   4.6 ± 0.3b 
  CD40 MFI   5.0 ± 0.2   4.8 ± 0.2   4.7 ± 0.3 
1 See Table 1 footnote 
 
Primary 
antibody 
specificity 
 
Clone 
 
Isotype 
 
Source 
 
Secondary  
antibody 
sIgM Big73A IgG1 VMRD αIgG1-PerCP 
sIgM PIG45A IgG2b VMRD αIgG2b-Cy5 
CD5 B29A IgG2a VMRD αIgG2a-PE 
B-B2 BAQ44a IgM VMRD αIgM-FITC 
CD25 LCTB2A IgG3 VMRD αIgG3-FITC 
CD21 GB25A IgG1 VMRD αIgG1-PerCP 
CD11a/18 BAT75A IgG1 VMRD αIgG1-PerCP 
CD40  IgG1 D.M. Estes αIgG1-PerCP 
CD80 BBI IgM Pharmingen αIgM-FITC 
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 Table 4. Effects of lymph node location on expression of 
activation molecules by OVA-stimulated sIgM+ cells. Calves 
were vaccinated with OVA on left side only at 3 and 5 wk of 
age. 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 * Means within a row differ (P ≤ 0.05) 
 
Figure 1. OVA and WCS-PK specific Ig in sera from 
vaccinated calves.  Calves were vaccinated with OVA only at 3- 
and 5-wk of age (OVA, n = 3) or vaccinated with BCG + OVA 
at wk 3 and OVA at wk 5 (OVA+BCG; n = 3).  Serum was 
collected before vaccination at 1- and 3-wk of age, and after 
vaccination at 5, 6, 7, and 8 wk of age.  Absorbances (mean + 
SEM) are shown. 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Location of lymph node  
Cell Phenotype Left Right 
OVA-stimulated   
  % CD5 positive 49.4 ± 4.3 66.2 ± 2.8* 
  CD5 MFI 25.3 ± 6.2 54.7 ± 8.5* 
  % B-B2 positive 54.0 ± 3.2 43.3 ± 2.8* 
  B-B2 MFI 12.0 ± 1.3   8.3 ± 0.6* 
  CD21 MFI   4.2 ± 0.2   4.9 ± 0.2* 
  CD25 MFI   7.0 ± 0.8   4.6 ± 0.3* 
  MHC-II MFI   9.2 ± 1.7   6.3 ± 0.8 
  CD11a/18 MFI   8.6 ± 0.9   9.9 ± 0.6 
  CD80 MFI   6.8 ± 0.5   5.4 ± 0.4 
  CD40 MFI   4.5 ± 0.3   5.0 ± 0.2 
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